Dominic Schwarz

Dominic Schwarz

Auto-generated profile, based on publicly available information

Dominic Schwarz

Faculty for Chemistry and Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2026 in Nature Biomedical Engineering
Verified
Journal Article
Open access
MGMar Guaza-Lasheras
Mar Guaza-Lasheras
JNJohanna Nimmerfroh
Johanna Nimmerfroh
DSDominic Schwarz
Dominic Schwarz
TGTanja D. de Grujil
Tanja D. de Grujil
JHJessica Hartmann
Jessica Hartmann
SKSebastian Kobold
Sebastian Kobold
Chimeric antigen receptor (CAR)-T cells represent a recent clinically validated modality in cancer therapy and beyond. However, broad industrial implementation faces technological, logistical, regulatory and financial challenges. A major bottleneck is the ex vivo production process, where cytokines are essential and product-determining constituents. To better understand the complexity of cytokine utilization throughout the production process, we rigorously reviewed the existing literature, including extended manufacturing parameters from 292 available clinical reports. We found a progressive reduction of interleukin-2 exposure, driven by its association with unfavourable cell characteristics. Preclinically, this catalysed the evaluation of alternative cytokines with potential to preserve naive phenotypes, support cell expansion and enhance the efficacy of CAR-T cells. Here we illustrate the evolving use of cytokines, reveal non-standardized clinical CAR-T cell manufacturing parameters, and summarize preclinical and next-generation concepts, which may improve manufacturing efficiency, cost-effectiveness and therapeutic outcomes. Our observations may further guide the development of cytokine-armouring strategies to promote in-patient expansion and persistence, even as innovations such as shortened manufacturing and in vivo engineering techniques could reduce reliance on cytokines during ex vivo culture.

30 May 2026 in Nature Communications
Verified
Journal Article
Open access
MMMateusz Mendel
Mateusz Mendel
DSDominic Schwarz
Dominic Schwarz
TSTao Sun
Tao Sun
STSophia Tan
Sophia Tan
AFAsia Franceschetti
Asia Franceschetti
LSLina Schukur
Lina Schukur
Precise transgene regulation is crucial for safe and effective gene and cell therapies. Current inducible systems often rely on immunogenic exogenous proteins or non-clinically approved inducers, hindering clinical translation. Here we present RisdiON, a compact inducible system controlled by risdiplam, a clinically approved oral drug that acts via splicing modulation. RisdiON utilizes risdiplam-responsive sequences for precise transgene control via endogenous splicing machinery, bypassing exogenous protein regulators, while its split-ATG architecture ensures the expression of native, tag-free proteins. This approach provides robust, dose-dependent induction with minimal leakiness. We demonstrate that RisdiON controls various transgenes in immortalized cell lines and hiPSCs, enables inducible CAR expression in primary T cells, and regulates Cas9 for precise gene editing. Additionally, we achieve reversible transgene expression in vivo using adeno-associated virus (AAV) delivery. The platform is modular and functional across diverse promoters, offering a safe, titratable, and reversible tool when coupled with an orally bioavailable drug to advance next-generation therapies.

10 August 2026 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
MGMar Guaza-Lasheras
Mar Guaza-Lasheras
JNJohanna Nimmerfroh
Johanna Nimmerfroh
DSDominic Schwarz
Dominic Schwarz
TGTanja D. de Gruijl
Tanja D. de Gruijl
JHJessica Hartmann
Jessica Hartmann
SKSebastian Kobold
Sebastian Kobold